Mayne Pharma Group (MYX) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
19 Nov, 2026Opening remarks and agenda
Agenda: Chair’s Address, Business Update, Formal Business and Close; Professor Bruce Robinson chaired, with CEO Aaron Gray leading the business update.
Financial performance review
FY26 revenue was A$383.7m, down 6% YoY; gross margin rose 4.1 percentage points to 64.7%, while underlying EBITDA fell 27% to A$34.2m.
FY26 direct segment contribution was A$107.1m, down 2%; adjusted operating cash flow from continuing operations was A$34.5m, down 24%; cash and marketable securities were A$80.0m at 30 June 2026.
Branded products rose to 83% of FY26 net sales from 79% in FY25, alongside gross margin expansion to 65% from 61%.
1Q FY27 revenue was A$95.7m, down 2% YoY; gross margin was 63%, underlying EBITDA A$5.3m, down 52%, and direct segment contribution A$23.3m, down 23%.
1Q FY27 Women’s Health revenue was US$34.4m, up 9% YoY, while Dermatology/DistributeRx revenue was US$18.9m, down 16%; respective direct contributions were US$12.8m and US$3.1m.
Board and executive committee updates
Directors and KMP listed: Chair Professor Bruce Robinson; CEO Aaron Gray; CFO Griffin Buchanan; and Non-Executive Directors Ann Custin, David Petrie, Meghan Rivera and Jacob Ma-Weaver.
Latest events from Mayne Pharma Group
- A$6.40 cash Scheme offers a 99.4% premium, with implementation expected in March 2027.MYX
Scheme meeting 2026 - MPI sale for AUD 55.5m lifts pro forma cash to AUD 122.8m and sharpens U.S. focus.MYX
Investor update - Women's Health and DistributeRx growth offset by Dermatology erosion and lower EBITDA.MYX
Q1 2027 TU - Branded mix rose to 83%, lifting FY26 gross margin to 64.7%.MYX
Investor presentation - Revenue down 6% to $383.7M, net profit $31.2M, gross margin up to 64.7%.MYX
H2 2026 - Gross margin rose to 65.3% as Dermatology drove contribution growth and net loss narrowed.MYX
H1 2026 - Underlying EBITDA up 105% to $47.0m, revenue $408.1m, Cosette deal advances.MYX
H2 2025 - Shareholders overwhelmingly approved a proposed A$7.40-per-share scheme, pending court and regulatory clearance.MYX
AGM 2025 - Revenue up 112% and underlying EBITDA positive, led by Women's Health and Dermatology growth.MYX
H2 2024